Bicarbonate

Bicarbonate

SCHEMBL120119

O=C([O-])[O-].O=C([O-])[O-].[Mg+2].[Mg+2].[Mg+2].[OH-].[OH-]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.46
CA1 P00915 3/20 0.46
FAHD1 Q6P587 1/20 0.46
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
LDHA P00338 1/20 0.36
BLM P54132 1/20 0.36
KMT2A Q03164 1/20 0.36
CASP1 P29466 1/20 0.33
CA2 P00918 1/20 0.30
CA9 Q16790 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL2354752 1.00
Bicarbonate SCHEMBL2304976 0.94
Bicarbonate SCHEMBL6577639 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL6579968 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL81419 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL17868581 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL720363 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL570556 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL2050659 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL3732974 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083648-A1 DEODORANT COMPOSITIONS AND METHODS OF MAKING SAME DR. SQUATCH, LLC (US) 2026-03-26 US claimed
EP-4714422-A1 COMPOSITION FOR ABSORBING SKIN PERSPIRATION AND/OR BODY MOISTURE Società Italo Britannica L. Manetti - H. Roberts & C.p.A. (IT) 2026-03-25 EP claimed
US-20250375362-A1 DEODORANT COMPOSITIONS PROCTER & GAMBLE (US) 2025-12-11 US claimed
US-20250352457-A1 DEODORANT COMPOSITIONS AND METHODS OF MAKING SAME DR. SQUATCH, LLC (US) 2025-11-20 US claimed
EP-4628066-A2 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS The Procter & Gamble Company (US) 2025-10-08 EP claimed
US-20250303676-A1 LAMINATE, USE THEREOF, AND METHOD OF MAKING THE SAME HEXION INC. 2025-10-02 US claimed
US-12420534-B2 Aerogel polysiloxane layer laminate structure DOW SILICONES CORPORATION (US) 2025-09-23 US claimed
EP-3768389-B1 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS PROCTER & GAMBLE (US) 2025-09-03 EP claimed
EP-3695832-B1 COMPOSITION FOR TREATING HAIR LOSS DUI CLINIQUE AS (NO) 2025-06-18 EP claimed
US-20250170524-A1 SYSTEM, APPARATUS, AND METHOD FOR ALKALINE EARTH METAL HYDROXIDE LOOPING FOR CARBON DIOXIDE REMOVAL FROM AIR PARALLEL CARBON INC (US) 2025-05-29 US claimed
US-4629628-A HIGH STRENGTH FERRERO OHG MBH (DE) 1986-12-16 US claimed
EP-0111747-B1 STORAGE-STABLE AGENT CONTAINING PYRAZOPHOS AND CAPTAFOL AS ACTIVE INGREDIENTS HOECHST AKTIENGESELLSCHAFT (DE) 1986-07-30 EP claimed
EP-0160015-A1 PREPARATION FOR REHYDRATING MONOGASTRIC ANIMALS, INCLUDING HUMAN BEINGS, SUFFERING FROM DIARRHOEA AND USE THEREOF. GJERLOV MOGENS 1985-11-06 EP claimed
EP-0150792-A2 Drugs and the use of poorly soluble compounds of calcium and/or magnesium for the production of drugs Algina Aktiengesellschaft (CH) 1985-08-07 EP claimed
WO-1985001441-A1 PREPARATION FOR REHYDRATING MONOGASTRIC ANIMALS, INCLUDING HUMAN BEINGS, SUFFERING FROM DIARRHOEA AND USE THEREOF GJERLOEV MOGENS 1985-04-11 WO claimed
EP-0111747-A1 Storage-stable agent containing pyrazophos and captafol as active ingredients HOECHST AKTIENGESELLSCHAFT (DE) 1984-06-27 EP claimed
EP-0022901-B1 WAFFLE AND PROCESS FOR ITS PRODUCTION Ferrero oHG (DE) 1984-06-20 EP claimed
EP-0011748-B1 PROCESS FOR PRODUCING POLYOLEFIN FOAMS HÜLS TROISDORF AKTIENGESELLSCHAFT (DE) 1982-12-01 EP claimed
US-4266041-A USING PEROXIDE CROSSLINKING AND FOAMING AGENTS UNDER NORMAL PRESSURE WITH MAGNESIUM OXIDE, HYDROXIDE OR BASIC CARBONATE PRESENT DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1981-05-05 US claimed
EP-0022901-A2 Waffle and process for its production Ferrero oHG (DE) 1981-01-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083648-A1 DEODORANT COMPOSITIONS AND METHODS OF MAKING SAME CUTA, DAGLA, LIPA CA4 1409/4885CA1 2680/4885FAHD1 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.